These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9285228)

  • 41. The concept of cost in the economic evaluation of health care. A theoretical inquiry.
    Johannesson M
    Int J Technol Assess Health Care; 1994; 10(4):675-82. PubMed ID: 7843887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multilevel mediation modeling in group-based intervention studies.
    Krull JL; MacKinnon DP
    Eval Rev; 1999 Aug; 23(4):418-44. PubMed ID: 10558394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Demand for health care in Denmark: results of a national sample survey using contingent valuation.
    Gyldmark M; Morrison GC
    Soc Sci Med; 2001 Oct; 53(8):1023-36. PubMed ID: 11556772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computing what the public wants: some issues in road safety cost-benefit analysis.
    Hauer E
    Accid Anal Prev; 2011 Jan; 43(1):151-64. PubMed ID: 21094309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discounting in economic evaluations: stepping forward towards optimal decision rules.
    Gravelle H; Brouwer W; Niessen L; Postma M; Rutten F
    Health Econ; 2007 Mar; 16(3):307-17. PubMed ID: 17006970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive modeling of total healthcare costs using pharmacy claims data: a comparison of alternative econometric cost modeling techniques.
    Powers CA; Meyer CM; Roebuck MC; Vaziri B
    Med Care; 2005 Nov; 43(11):1065-72. PubMed ID: 16224298
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis in heart disease, Part I: General principles.
    Kupersmith J; Holmes-Rovner M; Hogan A; Rovner D; Gardiner J
    Prog Cardiovasc Dis; 1994; 37(3):161-84. PubMed ID: 7972851
    [No Abstract]   [Full Text] [Related]  

  • 48. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?
    O'Hagan A; Stevens JW
    Health Econ; 2003 Jan; 12(1):33-49. PubMed ID: 12483759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conjoint analysis. The cost variable: an Achilles' heel?
    Slothuus Skjoldborg U; Gyrd-Hansen D
    Health Econ; 2003 Jun; 12(6):479-91. PubMed ID: 12759917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Performance of statistical models to predict mental health and substance abuse cost.
    Montez-Rath M; Christiansen CL; Ettner SL; Loveland S; Rosen AK
    BMC Med Res Methodol; 2006 Oct; 6():53. PubMed ID: 17067394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
    Hoerger TJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic evaluation of osteoporosis prevention.
    Johannesson M; Jönsson B
    Health Policy; 1993 May; 24(2):103-24. PubMed ID: 10126753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using discrete choice experiments to value health care programmes: current practice and future research reflections.
    Ryan M; Gerard K
    Appl Health Econ Health Policy; 2003; 2(1):55-64. PubMed ID: 14619274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.
    Gafni A
    Med Care; 1991 Dec; 29(12):1246-52. PubMed ID: 1745082
    [No Abstract]   [Full Text] [Related]  

  • 56. Quantifying the physician contribution to managed care pharmacy expenses: a random effects approach.
    Cowen ME; Strawderman RL
    Med Care; 2002 Aug; 40(8):650-61. PubMed ID: 12187179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are any numbers better than no numbers? The sorry state of willingness-to-pay and some major methodological shortcomings.
    Burrows C; Brown K
    Aust Health Rev; 1992; 15(2):135-44. PubMed ID: 10119045
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Theory and methods of economic evaluation of health care.
    Johannesson M
    Dev Health Econ Public Policy; 1996; 4():1-245. PubMed ID: 10158916
    [No Abstract]   [Full Text] [Related]  

  • 59. The usefulness of average cost-effective ratios.
    Laska EM; Meisner M; Siegel C
    Health Econ; 1997; 6(5):497-504. PubMed ID: 9353650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Theoretical arguments for the discounting of health consequences: where do we go from here?
    Lazaro A
    Pharmacoeconomics; 2002; 20(14):943-61. PubMed ID: 12403636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.